



Share a clinical case  
treated with Emdogain®  
with your fellow dental  
professionals.

# More than 20 years of periodontal regeneration – Straumann® Emdogain®

**YES, IT HAS BEEN 20 YEARS SINCE EMDOGAIN®  
WAS FIRST LAUNCHED IN EUROPE!**


Over the past 20 years, Straumann® Emdogain® has proven to be an effective solution to treat patients with periodontitis by inducing the regeneration of lost periodontal tissues, and to provide improved patient satisfaction (compared to other methods) thanks to better healing, less surgical complications, and long-term clinical benefits.

#### **Emdogain® in numbers:**

- Over 2 million patients treated<sup>1</sup>
- Stable results documented for over 10 years in 2 indications<sup>2</sup>
- Over 800 scientific publications
- Over 400 clinical publications
- Almost no side effects<sup>3</sup>



Post op  
Courtesy of Prof. Carlos Nemcovsky, Israel



20 years follow up

<sup>1</sup> Based on the number of syringes sold <sup>2</sup> McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: comparison of clinical parameters at 10 years. J Periodontol. 2012 Nov;83(11):1353-62/2. Sculean A, et al. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2008 Sep;35(9): 817-24 <sup>3</sup> Post surgery complication rate < 0.002%

**CELEBRATE WITH US THE 20TH ANNIVERSARY OF EMDOGAIN®,  
SHARE A CLINICAL CASE TREATED WITH EMDOGAIN® WITH YOUR  
FELLOW DENTAL PROFESSIONALS.**

**Where will the cases be shown?**

- All cases will be displayed on a digital platform of cases accessible worldwide.
- Selected cases will be included in the new Emdogain® casebook which will be published by the end of 2015.

**What is the process?**

- Fill out the online case collection form online at *straumann.com/EmdogainCases* OR
- Fill out the case collection form document available *at strau mann.com/ EmdogainCases* and submit it along with all the requested documentation to *regen@straumann.com*.
- Deadlines for submission:
  - General deadline: 31 December 2015
  - To be considered for the printed casebook: 19 June 2015

**Prize:**

- Everyone who submits a fully documented clinical case will receive a “20 years of Emdogain®” surgical suit!
- Three out of all cases with at least 12 years of follow-up that are being submitted before 19 June 2015 will be drawn and receive an iPad Air 2!  
iPad® is a trademark of Apple Inc., registered in the U.S. and other countries.

**SIGN UP TODAY TO BE AMONG THE FIRST  
CLINICIANS TO TRY STRAUMANN® OSTEOGAIN™!**

Straumann® Osteogain™ is a new biologic solution that has been developed and optimized for mixing with bone graft materials and collagen substrates to stimulate bone formation as part of regenerative bone augmentation procedures.

Register today on [straumann.com/osteogain](http://straumann.com/osteogain) and get your 3 free samples for clinical use!\*

\* as soon as Straumann® Osteogain™ is available in your market



**International Headquarters**

Institut Straumann AG

Peter Merian-Weg 12

CH-4002 Basel, Switzerland

Phone +41 (0)61 965 11 11

Fax +41 (0)61 965 11 01

[www.straumann.com](http://www.straumann.com)

© Institut Straumann AG, 2015. All rights reserved.

Straumann® and/or other trademarks and logos from Straumann® mentioned herein are the trademarks or registered trademarks of Straumann Holding AG and/or its affiliates.